Targapremir-210-TGP-210-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemETargapremir-210Cat.No.:HY-15861CASNo.:1049722-30-6Synonyms:TGP-210分?式:C??H??N??O?分?量:592.69作?靶點(diǎn):MicroRNA;Apoptosis作?通路:Epigenetics;Apoptosis儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:250mg/mL(421.81mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.6872mL8.4361mL16.8722mL5mM0.3374mL1.6872mL3.3744mL10mM0.1687mL0.8436mL1.6872mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.08mg/mL(3.51mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(3.51mM);ClearsolutionBIOLOGICALACTIVITY?物活性Targapremir-210(TGP-210)?種有效的、選擇性的miR-210(miRNA-210,microRNA-210)抑制劑。Targapremir-210以?親和?抑制pre-miR-210的加?(Kd~200nM)[1]。IC50&TargetIC50:200nM(miR-210,inMDA-MB-231cells)[1].體外研究Targapremir-210decreasesmaturemiR-210levelsinMDA-MB-231cellsculturedunderhypoxicconditions,withanIC50of-200nM[1].Targapremir-210(200nM)inducesMDA-MB-231cellsapoptosisisselectiveforthehypoxicenvironment.Targapremir-210inducescellsapoptosisunderhypoxicconditionsanddoesnotinduceapoptosisinMDA-MB-231cellsculturedinnormoxia[1].體內(nèi)研究Targapremir-210(100μLof200nM;singlei.p.injection)impedesMDA-MB-231triplenegativebreastcancer(TNBC)cellsproliferationinvivo.Targapremir-210isabletoreachthetumorandsustainfortheentire21-dayperiod,anddecreasestumorburdeninaTNBCmousemodel[1].AnimalModel:NOD/SCIDmiceweresubcutaneouslytransplantedcellsuspensionintobreastfatpads[1].Dosage:100μLof200nMAdministration:Singlei.p.injection24hpost-transplantationResult:Decreasedtumorgrowthasassessedbyluciferasesignalintensityandmassoftheresectedtumor.REFERENCES[1].CostalesMG,etal.SmallMoleculeInhibitionofmicroRNA-210ReprogramsanOncogenicHypoxicCircuit.JAmChemSoc.2017Mar8;139(9):3446-3455.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forr